Lilly TB initiative in-licenses compounds

The Lilly TB Drug Discovery Initiative received an exclusive license from Summit (LSE:SUMM) to a series of undisclosed, preclinical compounds to treat tuberculosis (TB) in developing countries. The initiative is responsible for R&D costs, while Summit will co-develop the compounds. Separately, not-for-profit Microbial Chemistry Research Foundation (Tokyo, Japan) donated to the initiative CPZEN-45, a naturally derived compound with an unknown mechanism of action that is in preclinical testing to treat TB. ...